Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30988427 | 0.98 | MEN1 (0.64) | MEN1KMT2ADNM1KDM4ETSHR | |
| SCHEMBL25751510 | 0.94 | MEN1 (0.71) | MEN1KMT2ADNM1KDM4ETSHR | |
| SCHEMBL16384405 | 0.92 | MEN1 (0.68) | MEN1KMT2ADNM1KDM4ETSHR | |
| SCHEMBL24485546 | 0.86 | DNM1 (0.63) | MEN1KMT2ADNM1KDM4ETSHR | |
| SCHEMBL47678 | 0.86 | DNM1 (0.60) | MEN1KMT2ADNM1 | |
| SCHEMBL1456344 | 0.86 | DNM1 (0.60) | MEN1KMT2ADNM1 | |
| SCHEMBL1527147 | 0.84 | DNM1 (0.72) | MEN1KMT2ADNM1KDM4ETSHR | |
| Hydrochloric Acid SCHEMBL21197510 | 0.84 | DNM1 (0.58) | MEN1KMT2ADNM1 | |
| SCHEMBL11402225 | 0.83 | DNM1 (0.77) | MEN1KMT2ADNM1KDM4ETSHR | |
| SCHEMBL25816837 | 0.83 | MEN1 (0.68) | MEN1KMT2ADNM1RECQLNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119326716-A | Compound dendrobium candidum oral liquid and preparation method thereof | 安徽神农泽中医药科技发展有限公司 | 2025-01-21 | — | — | CN | claimed |
| CN-117306315-A | Kraft paper antibacterial composite material for medicine packaging and preparation method thereof | 丽的包装(广东)有限公司 | 2023-12-29 | — | — | CN | claimed |
| CN-105612186-B | Reverse phase polymerization process | 巴斯夫欧洲公司 | 2018-10-26 | — | — | CN | claimed |
| CN-119326716-A | Compound dendrobium candidum oral liquid and preparation method thereof | 安徽神农泽中医药科技发展有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119340481-A | Electrolyte, battery cell and electricity utilization device | 宁德时代新能源科技股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-118749523-A | Resistant sanitary pest control composition containing oxazine amide and application thereof | 江苏功成生物科技有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-117306315-A | Kraft paper antibacterial composite material for medicine packaging and preparation method thereof | 丽的包装(广东)有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230293419-A1 | COSMETIC COMPOSITIONS COMPRISING DRAGLINE SPIDER SILK | SEEVIX MATERIAL SCIENCES LTD. (IL) | 2023-09-21 | — | — | US | disclosed |
| US-20230183763-A1 | METHOD FOR PREPARING A FATTY AMIDOALKYLDIALKYLAMINE | RHODIA OPERATIONS (FR) | 2023-06-15 | — | — | US | disclosed |
| WO-2023099324-A1 | PRODUCTION OF HIGHLY FUNCTIONALIZED POLYSACCHARIDES WITH IMPROVED BIODEGRADABILITY | RHODIA OPERATIONS (FR) | 2023-06-08 | — | — | WO | disclosed |
| US-20230135545-A1 | BIOMIMETIC G-QUARTET COMPOUNDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-05-04 | — | — | US | disclosed |
| WO-2010106097-A1 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100043151-A1 | HAIR DYE AND APPLICATOR FOR HAIR USING THE SAME | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| CN-1662499-A | Cationic alkoxyamines and their use in the preparation of nanoparticles from natural or synthetic clays | CIBA SC HOLDING AG (CH) | 2005-08-31 | — | — | CN | disclosed |
| EP-1366018-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.P.A. (IT) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002068377-A1 | OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS | Dompé S.p.A. (IT) | 2002-09-06 | — | — | WO | disclosed |
| US-4267102-A | Bleomycin group antibiotics | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-05-12 | — | — | US | disclosed |
| US-RE30451-E | ANTITUMOR AGENTS | Zaidan Jojin Biseibutsu Kagaku Kenkyu Kai (JP) | 1980-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135545-A1 | BIOMIMETIC G-QUARTET COMPOUNDS | PYM1, B4GALT1, NGLY1 | MEN1 58/4885KMT2A 1478/4885DNM1 1139/4885 |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | MEN1 3684/4885KMT2A 1401/4885DNM1 3004/4885 |
| US-20100043151-A1 | HAIR DYE AND APPLICATOR FOR HAIR USING THE SAME | RAD52, AR, ADH1A | MEN1 4299/4885KMT2A 760/4885DNM1 4264/4885 |
| US-20230293419-A1 | COSMETIC COMPOSITIONS COMPRISING DRAGLINE SPIDER SILK | MSH6, TYR, PDE7B | MEN1 200/4885KMT2A 4456/4885DNM1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.